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Recent studies have provided evidence that breast
cancer susceptibility gene products (Brca1 and Brca2)
suppress cancer, at least in part, by participating in
DNA damage signaling and DNA repair. Brca1 is hyper-
phosphorylated in response to DNA damage and co-lo-
calizes with Rad51, a protein involved in homologous-
recombination, and Nbs1zMre11zRad50, a complex
required for both homologous-recombination and non-
homologous end joining repair of damaged DNA. Here,
we report that there is a qualitative difference in the
phosphorylation states of Brca1 between ionizing radi-
ation (IR) and UV radiation. Brca1 is phosphorylated at
Ser-1423 and Ser-1524 after IR and UV; however, Ser-
1387 is specifically phosphorylated after IR, and Ser-
1457 is predominantly phosphorylated after UV. These
results suggest that different types of DNA-damaging
agents might signal to Brca1 in different ways. We also
provide evidence that the rapid phosphorylation of
Brca1 at Ser-1423 and Ser-1524 after IR (but not after
UV)islargelyataxiatelangiectasiamutated(ATM)kinase-
dependent. The overexpression of catalytically inactive
ATM and Rad3 related (ATR) kinase inhibited the UV-
induced phosphorylation of Brca1 at these sites, indicat-
ing that ATR controls Brca1 phosphorylation in vivo
after the exposure of cells to UV light. Moreover, ATR
associates with Brca1; ATR and Brca1 foci co-localize
both in cells synchronized in S phase and after exposure
of cells to DNA-damaging agents. ATR can itself phos-
phorylate the region of Brca1 phosphorylated by ATM
(Ser-Gln cluster in the C terminus of Brca1, amino acids
1241–1530). However, there are additional uncharacter-
ized ATR phosphorylation site(s) between residues 521
and 757 of Brca1. Taken together, our results support a
model in which ATM and ATR act in parallel but some-
what overlapping pathways of DNA damage signaling
but respond primarily to different types of DNA lesion.
Damage to DNA, which can occur from exogenous agents
such as IR,1 UV radiation, and certain chemotherapeutic drugs
or from endogenously generated reactive oxygen species, poses
a great threat to genomic stability. Cells respond to DNA dam-
age by activating a complex DNA damage-response pathway
that includes cell cycle arrest, transcriptional and posttran-
scriptional regulation of genes associated with repair, and un-
der some circumstances, the triggering of programmed cell
death. Biochemically, the DNA damage-response pathway pro-
vides a mechanism for transducing a signal from a sensor that
recognizes the damage, through a transduction cascade, to a
series of downstream effector molecules, which implement the
appropriate response. At or close to the top of this pathway in
mammalian cells are the members of the phosphoinositide
kinase-related kinase (PIKK) family, which includes ATM
(ataxia telangiectasia mutated) and ATR (ATM and Rad3 re-
lated). These proteins play important roles in signaling the
presence of DNA damage, activating cell cycle checkpoints, and
repairing DNA (1). ATM is homozygously mutated in the germ-
line of patients with the neurodegenerative and cancer predis-
position syndrome, ataxia telangiectasia (AT). Cells derived
from AT patients are hypersensitive to agents that cause dou-
ble strand breaks in DNA, such as IR, but retain normal re-
sistance to UV and other damaging agents. AT cells exhibit cell
cycle defects at multiple checkpoints (G1/S, intra S, and G2/M)
in response to IR. ATM-deficient mice are viable but show
growth retardation and a cancer predisposition. In mammals,
ATM is an upstream regulator of p53, c-Abl, Chk2 (hCds1),
Brca1, and nibrin in response to IR (2, 3). Less is known about
ATR because no ATR mutations have been detected in human
diseases. However, the overexpression of the dominant nega-
tive ATR derivative in mammalian cells sensitizes them to a
range of DNA-damaging agents (4). The homozygous inactiva-
tion of ATR in mice results in the early embryonic lethality
associated with the loss of cellular proliferative potential and
chromosomal fragmentation leading to mitotic catastrophe, a
phenotype reminiscent of the phenotype of the Brca1-null em-
bryos (5, 6). Recent studies have provided evidence that Brca1
suppresses cancer, at least in part, by participating in the
signaling of DNA damage and DNA repair (7, 8). Brca1 is
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aging agents (9), indicating that it is a target of protein kinases
activated by DNA damage. We and others have recently pro-
vided evidence that ATM and ATM-dependent kinase Chk2
mediate the phosphorylation of Brca1 after IR (10–12). ATM is
required only for the rapid and immediate phosphorylation of
Brca1 after IR because Brca1 is still phosphorylated in ATM-
null cells, albeit with delayed kinetics (11). Furthermore, the
phosphorylation of Brca1 after UV and hydroxyurea is ATM-
independent (13) and probably mediated by ATR because ATM
and ATR have been shown to have overlapping substrate spec-
ificity in vitro (14). Despite the apparent overlap of function
between ATM and ATR, it has been clearly shown that the
immediate phosphorylation of p53 in response to IR is largely
ATM-dependent, whereas ATR mediates the UV-induced rapid
phosphorylation of p53. Recently, evidence has been presented
that ATR regulates the phosphorylation of human Chk1 in
response to UV treatment (15). Therefore, this study was de-
signed to investigate the role of ATR in UV-induced modifica-
tions of Brca1. During the preparation of this manuscript,
similar studies have suggested the role of ATR in Brca1 phos-
phorylation (13, 16). However, using phospho-specific antibod-
ies, our results provided further details of BRCA1 phosphory-
lations at various sites by ATM and ATR. We found that ATM
and ATR, in addition to their shared phosphorylation sites, also
phosphorylate distinctively different sites in BRCA1 in vivo.
EXPERIMENTAL PROCEDURES
Constructs and Recombinant Proteins—Epstein-Barr virus-trans-
formed lymphoblastoid cell lines generated from normal controls and
AT patients have been described previously (17). The generation and
characterization of GM847 cells that express wild-type (wt) or kinase-
dead (kd) ATR under the control of the bacterial tet operator have been
described previously (4). Lymphoblastoid cell lines were cultured in
RPMI 1640 medium supplemented with 10% fetal calf serum at 37 °C in
a humidified atmosphere of 5% CO2. The SV40-transformed GM847
cells were grown in Dulbecco’s modified Eagle’s medium containing 10%
fetal calf serum. Following transfection, cells were grown in complete
medium containing G418 (Life Technologies, Inc.). The expression of wt
and kd ATR was induced by incubating the cells in culture medium
containing 1 mM doxycycline (Sigma) for 48 h. Cells were grown to 80%
confluence and then treated with either IR or UV light. The indicated
cells were irradiated (6 Gy) with a 137Cs g-ray source or exposed to
UV-C (80 J/m2).
Antisera and Plasmid Constructs—Phospho-specific antibodies
against ATM phosphorylation sites in BRCA1 (anti-Ser-1423, anti-Ser-
1457, and anti-Ser-1387) have been described previously (11). Anti-
phospho-Ser-1524 rabbit antiserum was generated in this study by
immunizing with keyhole limpet hemocyanin-conjugated phosphopep-
tide (QNRNYP-Phospho-Ser(P)-QEELIK). Bleeds were assayed by en-
zyme-linked immunosorbent assay, and the serum was collected on
days corresponding to the peak antibody response and then affinity-
purified against the same peptide. The affinity-purified polyclonal an-
tibodies recognized the phosphorylated form of a Brca1 peptide but not
the unphosphorylated form employing an enzyme-linked immunosor-
bent assay. Anti-BRCA1 monoclonal antibodies (Ab-1) and anti-ATR
polyclonal antibodies were from Oncogene Science, Inc. (Manhasset,
NY). Anti-FLAG was purchased from Sigma. A series of glutathione
S-transferase (GST)-BRCA1 fusion proteins was generated and purified
as described previously (11).
Immunoblotting, Co-immunoprecipitation, and Kinase Assays—Cel-
lular extracts were prepared by resuspending the cells in lysis buffer
(50 mM Tris-HCL, pH 7.4, 150 mM NaCl, 2 mM EGTA, 2 mM EDTA, 25
mM NaF, 25 mM b-glycerophosphate, 0.1 mM sodium orthovandate, 0.1
mM phenylmethylsulfonyl fluoride, 5 mg/m1 leupeptin, 1 mg/ml aproti-
nin, 0.2% Triton X-100, and 0.3% Nonidet P-40) and incubating on ice
for 30 min. Supernatants were collected following centrifugation at
14,000 3 g for 15 min. 40 mg of protein/sample was then analyzed by
SDS-polyacrylamide gel electrophoresis and immunoblotting with the
appropriate antibodies. For co-immunoprecipitations, protein samples
were precleared with protein A beads for 1 h at 4 C. The supernatants
were then incubated with the required antibody for 2 h. The immune
complexes were collected with protein A- and G-Sepharose beads. The
complexes were washed twice with lysis buffer and then fractionated by
SDS-polyacrylamide gel electrophoresis for immunoblot analysis. For
kinase assays, cells were lysed in TGN buffer (50 mM Tris-HCl, pH 7.5,
50 mM b-glycerophosphate, 150 mM NaCl, 10% glycerol, 1% Tween 20,
1 mM NaF, 1 mM sodium orthovandate, 1 mM phenylmethylsulfonyl
fluoride, 2 mg/ml pepstatin, 10 mg/ml aprotinin, 5 mg/ml leupeptin, and
1 mM dithiothreitol) as described previously (18). The immunoprecipi-
tation was carried out as described above using either anti-ATR or
anti-FLAG antibodies. The immunoprecipitates were washed twice
with TGN buffer, once with 100 mM Tris-HCl (pH 7.5) and 0.5 M LiCl,
and twice with kinase buffer (10 mM Hepes, pH 7.5, 50 mM b-glycero-
phosphate, 50 mM NaCl, 10 mM MgCl2, 10 mM MnCl2, 5 mM ATP, and 1
mM dithiothreitol). Kinase reactions were prepared by resuspending
washed beads in 30 ml of kinase buffer containing 10 mCi of [g-32P]ATP
and 1 mg of GST-BRCA1 fusion protein. Immune complex reactions
were incubated at 30 °C for 30 min and analyzed by SDS-polyacryl-
amide gel electrophoresis followed by autoradiography.
Immunofluoresence Studies—Cells were synchronized by a double
thymidine block at the G1/S transition and then released into thymi-
dine-free medium for a synchronous passage through S phase. 2 h after
release, cells were either left untreated or irradiated at 10 Gy, and 4 h
after exposure, cells were fixed in methanol:acetone (1:1) at 220 °C,
washed in phosphate-buffered saline, and blocked with a blocking so-
lution (3% bovine serum albumin, 0.1% Triton in phosphate-buffered
saline). For double labeling with rabbit (anti-ATR) and mouse (anti-
Brca1) antibodies, cells were incubated with a mixture of antibodies for
2 h at 4 °C. Cells were then washed three times in phosphate-buffered
saline and incubated with a mixture of fluorescein-labeled anti-rabbit
IgG (Zymed Laboratories Inc.) and indocarbocyanine-labeled anti-
mouse IgG (Zymed Laboratories Inc.) for 30 min. After extensive wash-
ing, samples were mounted onto glass slides with a drop of anti-fade
mounting reagent (Vectashield, Vector Laboratories). Samples were
analyzed with a confocal laser scanning microscope (Bio-Rad). Images
were digitally captured and overlaid using the RGB function of Adobe
Photoshop.
RESULTS
Ultraviolet or g Irradiation and Brca1 Phosphorylation—We
previously raised anti-phospho-specific antibodies against
three of the ATM phosphorylation sites in Brca1 (Ser-1387,
Ser-1423, and Ser-1457). In this report, polyclonal rabbit anti-
bodies against an additional ATM phosphorylation site in
Brca1 (Ser-1524) were produced, affinity-purified, and termed
a-1524. In the present study, we monitored the phosphoryla-
tion of Brca1 in intact cells by using the phospho-specific anti-
bodies. Control and AT cells were exposed to IR (6 Gy) or UV
radiation (80 J/m2), and the cells were harvested for Western
blot analysis 30 min after damage. The Brca1 protein level and
phosphorylation state were then analyzed by Western blotting
by using anti-Brca1 (Ab-1, Oncogene Science) or phospho-spe-
cific antibodies (a-1387, a-1423, a-1457, and a-1524) against
ATM phosphorylation sites in Brca1. In agreement with our
earlier study (11), Brca1 phosphorylation after IR but not after
UV was ATM-dependent (Fig. 1). The a-1524 and a-1423 anti-
bodies detected an increased level of phosphorylation of Brca1
after UV and IR. The IR-induced phosphorylation was clearly
ATM-dependent because ATM-deficient cells (L3) failed to
show increased phosphorylation at these sites; however, UV-
C-induced phosphorylation was ATM-independent. Immuno-
blotting with a-1457 also revealed dramatically increased lev-
els of phosphorylated Brca1 in response to UV but not in
response to IR (Fig. 1). Again, this UV-C-induced increase was
ATM-independent. However, previously (11) we have shown
that a-1457 did detect phosphorylated Brca1 after IR when
Brca1 was immunoprecipitated from cell lysate (1 mg) with
anti-Brca1 antibody (Ab-1) followed by blotting with a-1457.
These results suggest that only a small fraction of Brca1 is
phosphorylated at this site after IR, which is below the thresh-
old level of detection after straight Western blot. However, a
significant proportion of Brca1 is phosphorylated at Ser-1457
after UV. By contrast the a-1387 antibodies detected an in-
crease in Brca1 phosphorylation after IR but not after UV
radiation.
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Role of ATR in Damage-induced Phosphorylation of Brca1—
Both ATM and ATR are members of the PIKK family and
contribute to the phosphorylation and accumulation of p53
after cellular exposure to g and UV radiation, respectively (19,
20). No ATR mutations have so far been documented in human
disease; therefore, human cell lines that carry mutant ATR are
not available. Furthermore, a homozygous knockout of ATR in
mice is embryonic lethal (5, 6). Therefore, for this study we
have used cells transfected with FLAG-tagged kd ATR, which
has previously been shown to exert a dominant negative effect
(4). Cells were induced with 1 mM doxycycline for 48 h to allow
the expression of transfected cDNA prior to harvesting. West-
ern blotting of cell lysates using anti-FLAG antibody revealed
the presence of ectopic ATR protein induced with doxycycline
(Fig. 2A). This protein was not detected in untransfected
GM847 cells. Immunoblotting of cell lysates with the anti-ATR
antibody, which recognizes both endogenous and ectopic ATR,
revealed an approximately 2–3-fold increase in ATR protein
expression after the cells were induced with doxycycline (Fig.
2A). The extracts from uninduced and induced cells transfected
with kd ATR, with and without prior exposure to IR (6 Gy) and
UV (80 J/m2), were analyzed for damage-induced modifications
of Brca1 by Western blotting with a-Brca1 (Ab-1) and various
anti-phospho-specific antibodies (a-1524, a-1457, a-1423, and
a-1387) against Brca1. The results, shown in Fig. 2B, clearly
demonstrate that the immediate UV-induced mobility shift of
Brca1 is compromised in cells overexpressing kd ATR protein.
This is reflected as the markedly reduced phosphorylation of
Brca1 on serine residues 1524, 1423, and 1457 in these cells in
response to UV (but not IR), suggesting thereby that rapid
UV-induced modifications of Brca1 are dependent upon the
presence of functional ATR kinase.
ATR Phosphorylates Brca1 Directly—Recently it has been
shown that Brca1 exists as a part of a complex designated
Brca1-associated genome surveillance complex that includes
putative DNA damage sensors such as ATM (21). Therefore, we
were interested in determining whether ATR exists in complex
with Brca1. To study this association, cell lysates were co-
immunoprecipitated with either anti-Brca1 or anti-ATR anti-
bodies. The immunoblot analysis of the ATR immunoprecipi-
tates with anti-Brca1 antibody demonstrated an interaction
between the two proteins in control and AT cell lines, indicat-
ing that the interaction between ATR and Brca1 is ATM-inde-
pendent (Fig. 3A). Similar results were obtained when Brca1
immunoprecipitates were blotted with the ATR antibody. The
specificity of this association was confirmed by immunoprecipi-
tation with nonspecific immunoglobulin, which failed to show
an ATR or Brca1 band after blotting with the respective anti-
bodies (results not shown). We next sought to examine whether
ATR and Brca1 co-localize in cells with or without the prior
treatment of cells with DNA damage. Prior to DNA damage,
the majority of cells stained with anti-ATR antibodies indicated
a nuclear diffuse pattern of staining. However, about 15% of
the cells exhibit a punctate pattern (foci) of staining in the
nucleus (data not shown). The synchronization of cells in S
phase by a double thymidine block caused a dramatic increase
in the proportion of cells exhibiting ATR foci (Fig. 3B). In
synchronized cells, ATR foci overlapped Brca1 foci. The stain-
ing pattern of ATR and Brca1 also overlapped extensively at
4 h after the treatment of cells with IR and UV (Fig. 3B),
indicating that the damage-induced modification of Brca1 by
ATR might contribute to changes in Brca1 subnuclear localiza-
tion after DNA damage. To investigate this possibility, we
sought to examine whether the phosphorylated Brca1 is a part
of the Brca1 foci induced after DNA damage by using a phos-
pho-specific antibody against Ser-1524. Most of the undamaged
cells (.85%) stained negative for the a-Ser-1524 antibody;
however, by 4 h after the treatment of cells with IR or UV,
.80% of cells exhibited the presence of phosphorylated Brca1
as nuclear foci (Fig. 3B). Most of the foci observed after staining
cells with the anti-Brca1 antibody (which detects both phos-
phorylated and nonphosphorylated Brca1) co-localized with the
foci observed with the phospho-specific antibody, indicating
FIG. 1. ATM is required for IR-induced phosphorylation of
Brca1 but is not required to phosphorylate Brca1 following UV
treatment. Synchronously growing cultures from the control lympho-
blastoid cell line (C3ABR) and ATM-deficient cell line (L3) were exposed
to either IR (6 Gy) or UV-C (80 J/m2) and harvested at 30 min after
treatment. The proteins were analyzed by Western blotting (WB) with
anti-BRCA1 (detects total pool of Brca1: phosphorylated and unphos-
phorylated) and anti-phospho-specific Brca1 antibodies against ATM
phosphorylation sites in Brca1 (a-1524, a-1457, a-1423, and a-1387).
FIG. 2. Rapid UV-induced phosphorylation of Brca1 is depend-
ent upon the presence of functional ATR kinase. A, inducible
expression of ATR wt and kd in GM847 (GM) fibroblasts. Immunoblot-
ting with anti-FLAG or anti-ATR antibodies was carried out in the
presence (1) or absence (2) of 1 mM doxycycline (dox) for 48 h prior to
harvesting the cells. WB, Western blot. B, ATR is required for the
UV-induced phosphorylation of Brca1. wt or kd ATR-transfected cells
were induced with 1 mM doxycycline (dox) for 48 h. After induction, the
cells were treated with either IR (6 Gy) or UV-C (80 J/m2) and harvested
30 min following damage. Proteins were fractionated by SDS-polyacryl-
amide gel electrophoresis and immunoblotted with anti-Brca1 and anti-
phospho-specific Brca1 antibodies. GM, GM847. WB, Western blot.
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that the phosphorylation of Brca1 at Ser-1524 may be essential
for regulating the localization of Brca1.
To test whether Brca1 is a direct target for the protein kinase
activity of ATR, we used a series of recombinant GST-Brca1
fragments (B1F1–B1F7) covering the entire open reading
frame (11). Kinase reactions were performed with purified im-
munoprecipitated ATR with or without prior exposure to UV.
Immunoprecipitated ATR from control lymphoblastoid cell
lines phosphorylated the region in Brca1, B1F6 (amino acids
1241–1530 (Fig. 3C)); the same region was previously shown to
be phosphorylated by ATM (11). This activity was also observed
against an additional Brca1 fusion protein not phosphorylated
by ATM, B1F3 (amino acids 521–757 (Fig. 3C)). None of the
other Brca1-GST fusion proteins were phosphorylated by ATR.
Immunoprecipitated ATR from ATM-deficient cells showed a
similar phosphorylation of fragments 3 and 6 (data not shown),
indicating that the activation of ATR is independent of ATM
expression in cells. Although ATR is activated in vivo after the
UV-C treatment of cells (demonstrated in Fig. 2B), we were
experimentally unable to show the increased activation of ATR
after UV-induced DNA damage in vitro. Ectopically expressed
FLAG-tagged wt ATR revealed a similar phosphorylation of
Brca1 at these sites (B1F6 is shown in Fig. 3D), whereas kd
ATR failed to show any activity against Brca1, thus providing
a specific control for ATR kinase activity (Fig. 3D).
DISCUSSION
The present results demonstrate that there is a qualitative
difference in Brca1 phosphorylation between g radiation and
UV radiation. Brca1 is phosphorylated at Ser-1423 and Ser-
1524 after both IR and UV. However, Ser-1387 is specifically
phosphorylated after IR, and Ser-1457 is predominantly phos-
phorylated after UV. These different responses in the phospho-
rylation of Brca1 after UV and IR exposure correspond to the
fact that the nature of DNA damage caused by these two
treatments is distinct; IR produces single or double strand
breaks followed by ligation or recombination repair, whereas
UV produces cyclobutane dimers followed by excision repair.
The cellular molecules that detect and repair these distinct
DNA lesions are different, which could well explain why the
Brca1 response is also different. For example, ATM-deficient
cells are defective in the cellular responses to double strand
FIG. 3. Direct interaction and phosphorylation of BRCA1 by ATR. A, in vivo association of ATR and Brca1. Total cell lysates were
subjected to immunoprecipitation (IP) with either anti-ATR or anti-Brca1 antibody, and the immunoprecipitated proteins were analyzed by
immunoblotting with anti-Brca1 and anti-ATR antibodies. WB, Western blot. B, co-localization of ATR and Brca1 in cells synchronized in S phase
(top panel, middle panel). Cells were synchronized by double thymidine block and then released into the fresh medium and cultured for 2 h. The
cells were then either left untreated (top) or treated with either IR (10 Gy) or UV-C (20 J/m2) (middle) in m2. 4 h after treatment, cells were fixed,
permeabilized, and stained with anti-ATR polyclonal antibody (Ab-1, Oncogene Science) and anti-Brca1 monoclonal antibody (Ab-1, Oncogene
Science). Foci demonstrating coincident labeling with both antibodies appear yellow in the merged picture. Bottom panel, Brca1 phosphorylated
on Ser-1524 localizes to nuclear foci. Normal human fibroblasts were fixed and permeabilized at 4 h after exposure to 10 Gy. Cells were then
immunostained with a phospho-specific anti-Brca1 (a-1524) antibody and anti-Brca1 monoclonal antibody (Ab-1) that detects both unphospho-
rylated and phosphorylated Brca1. Foci that stain with both antibodies appear yellow in the merged picture. C, ATR phosphorylates Brca1 directly.
Asynchronously growing cells were either untreated or treated with UV-C (80 J/m2) and then harvested at 30 min. ATR was immunoprecipitated
using anti-ATR antibodies and assayed with Brca1 fragments (B1F1–B1F7) as substrates. D, wt but not kd ATR phosphorylates a fragment of
Brca1. Whole cell lysates from uninduced, induced (dox) plus IR-treated, or induced plus UV-treated cells were immunoprecipitated with
anti-FLAG antibodies to precipitate ectopic ATR and assayed for the phosphorylation of Brca1 (B1F6). GM, GM847. WB, Western blot.
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break-inducing agents (such as IR and other radiomimetic
agents) but have a normal response to UV (22). However, there
is not an absolute requirement for ATM in the cellular response
to double strand breaks because the stabilization and phospho-
rylation of p53 (19, 22) is delayed but not abrogated in ATM-
deficient cells in response to IR. Recently, the ATM-related
kinase ATR was shown to mediate this late phosphorylation of
p53 on Ser-15 in response to IR and the early phosphorylation
of p53 in response to UV (20). These distinctions in kinetics
may be a consequence of dynamic changes in initiating damage
during the cellular exposures to IR and may dictate the need
for particular components of the damage response pathway at
particular times. These experiments reveal that the primary
genetic damages induced by IR may initially activate ATM and,
subsequently, that ATR is required to recognize the late DNA
strand breakage. Moreover, these experiments also suggest
that UV radiation may up-regulate the catalytic activity of ATR
efficiently rather than regulating ATM activity. Although the
mechanism by which ATM and ATR kinases are selectively
regulated by distinct DNA damage signals remains unclear at
present, it seems reasonable to propose that distinct DNA
damage detectors might act to identify different types of DNA
damage and that these distinct detectors might signal to Brca1
in a different way. ATR may be used immediately after UV
damage, and ATM may be used after IR to detect damage in the
DNA and then add phosphate groups to Brca1.
We have shown here that ATM is involved in the immediate
phosphorylation of Brca1 at multiple sites (Ser-1387, Ser-1423,
and Ser-1457) after IR but not after UV, which is consistent
with accumulating data that ATM is primarily involved in the
signaling of double strand breaks in DNA. The finding that the
overexpression of catalytically inactive ATR inhibits the UV-
induced phosphorylation of Brca1 at Ser-1423, Ser-1457, and
Ser-1524 strongly suggests that the phosphorylation of BRCA1
in response to UV requires the presence of functional ATR. The
precise mechanism by which the ATM- and ATR-dependent
phosphorylation of Brca1 regulate Brca1 function is unclear at
present. It is possible that phosphorylation might lead to a
change in Brca1 subnuclear localization, which changes in
response to DNA damage. In this regard, we observed that the
Brca1 pool in cells is phosphorylated on Ser-1524 in response to
IR and UV, and this phosphorylated form localizes to nuclear
foci within 2 h after DNA damage, suggesting that phosphoryl-
ation might regulate the localization of Brca1. Interestingly,
ATR also forms nuclear foci in cells synchronized in S phase,
and these foci co-localize with Brca1. This observation is con-
sistent with the essential roles of ATR and BRCA1 during the
normal cell cycle, possibly facilitating DNA replication and
preventing mitotic entry during S phase. A majority of cells in
asynchronous culture show ATR-containing nuclear foci when
exposed to DNA damage (IR and UV). Because an increase in
ATR kinase activity has not been observed after treatment
with various DNA-damaging agents, it is possible that ATR is
regulated by its location to its substrate, such as BRCA1, after
DNA damage. These results are also consistent with an earlier
report that demonstrated the co-localization of Brca1 and ATR
onto asynapsed regions of meiosis I chromosomes (23) and
could represent the primary response to early lesions, which
might initiate meiotic recombination and synapsis. It is quite
conceivable that the ATRzBrca1 complex might control homol-
ogous recombination and homology-directed repair in somatic
cells. The fact that ATR and BRCA1 mutant mice share similar
phenotypes (5) and that ATR controls BRCA1 phosphorylation
suggests that ATR is a key regulator of BRCA1 function. Un-
covering the biochemical details of signaling to Brca1 will be an
important step toward understanding why the defects in this
gene product predispose people to breast cancer.
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